Verbatim response from ChatGPT
Short answer
- On average, tirzepatide (Zepbound — a brand of tirzepatide for weight loss) produces larger mean weight loss in clinical trials than semaglutide (Wegovy).
- Easier to get online today: semaglutide (Wegovy or off‑label semaglutide/Ozempic) is generally easier to obtain through telehealth and weight‑loss clinics. Zepbound/tirzepatide is newer and in higher demand, so access is more limited for many patients.
Why (brief)
- Efficacy: Tirzepatide is a dual GIP/GLP‑1 receptor agonist; trials have shown greater average percent weight loss than semaglutide (a GLP‑1 agonist) at the doses used for obesity. That means Zepbound tends to produce larger weight loss for many people in head‑to‑head‑style comparisons reported in the literature.
- Side effects and safety: Both drugs commonly cause gastrointestinal side effects (nausea, vomiting, diarrhea, constipation). Both carry similar class warnings (e.g., potential risk for thyroid C‑cell tumors in rodents; not recommended with a personal/family history of medullary thyroid carcinoma or MEN2). The overall safety profile is comparable but individual tolerability varies.
- Availability: Wegovy has been on the market longer for weight management; telehealth weight programs, concierge clinics, and many online services commonly prescribe semaglutide (Wegovy or off‑label semaglutide/Ozempic). Zepbound (tirzepatide for weight) is newer and demand has made it harder to find in some areas; tirzepatide used for diabetes (Mounjaro) has also experienced supply pressures.
Practical points about getting them online
- Both require a prescription and medical evaluation. Reputable telehealth services and weight‑management programs can evaluate you remotely and prescribe if appropriate. Expect to provide medical history, current meds, and sometimes lab results.
- Telehealth providers that commonly prescribe GLP‑1s/GLP/GIP drugs: Calibrate (structured weight‑loss program), Hims & Hers, Ro (Roman), PlushCare, One Medical, and many dedicated obesity clinics. Some of these offer coaching, insurance support/prior‑auth help, and pharmacy fulfillment.
- Insurance and cost: Coverage varies a lot. Many insurers require prior authorization and have clinical criteria. Out‑of‑pocket cost can be high; GoodRx, manufacturer savings programs, or pharmacy discount plans can help but check coverage first.
- Avoid unverified online sellers or buying injectables without a prescription — safety risk.
Which should you choose?
- If your priority is the largest average weight loss and your clinician agrees you’re a candidate, tirzepatide (Zepbound/tirzepatide) is likely the more effective option based on current trial data.
- If access, established availability, or participating telehealth programs matter more, semaglutide (Wegovy or prescribed semaglutide) is often easier to obtain online now.
Next steps
- Discuss with your primary care physician or a board‑certified obesity medicine clinician who can review your medical history, contraindications, insurance, and monitor you. If you want an online route, consider one of the named telehealth clinics above and ask about their experience with Wegovy versus Zepbound/tirzepatide and how they handle insurance/prior authorization.
If you want, I can:
- Help compare likely out‑of‑pocket cost estimates for each based on your insurance (if you tell me insurer/type), or
- Look up which telehealth services currently list Wegovy or Zepbound prescribing for your state (tell me your state).